Venture Capital Access Online | The eMarketplace for the Venture Capital Industry

 

Bookmark and Share   

Home

Marketplace
Database
Deals
News
Store
Resources
Contact Us

 

 

 

News

VCPro Database 2014 (17th Edition) Now Available! Newly released


Venture Capital Deals Spreadsheet Now Available Newly released


 

TNG Pharmaceuticals, Inc. Closes $4.6 Million Series A Financing

LOUISVILLE, Ky., February 6, 2014-- TNG Pharmaceuticals, Inc. (TNG), an animal pharmaceutical company developing an innovative vaccine for cattle to aid in control of the horn fly, announced that it completed a $4.6 million Series A Preferred Stock financing on December 31, 2013.

The company’s FlyVax™ product is a patented vaccine designed to significantly reduce the damage caused by horn flies, thus improving the health and wellbeing of cattle. The revolutionary veterinary vaccine, first developed by research scientists at Auburn University and licensed by TNG, has been shown to be effective in initial laboratory testing.

According to Serge Martinod (DVM, PhD), CEO of TNG, “This important round of funding will allow us to complete all phases of product development necessary to commercialize the vaccine in a timely fashion.”

Phoebe Wood, Executive Chairman, added, “We are pleased that TNG was able to attract a group of outstanding investors led by the Yearling Fund. Other investors include Angel Investor Investment Management Group, Bluegrass Angels, Commonwealth Seed Capital, LLC, Goose Society of Texas, the Ogle Foundation, Texas Halo Fund, the University of Louisville Foundation and several individual and institutional investors. We believe the company is well positioned for future growth and its revolutionary product will lead to tremendous monetary savings for the cattle industry.”

About TNG Pharmaceuticals, Inc.

TNG Pharmaceuticals is a Louisville, KY based animal pharmaceutical company focused on the development of its patented vaccine for cattle, FlyVax™, to aid in control of the horn fly. The company began at the University of Louisville in the Entrepreneurship MBA program and was named 2011 Global Business Plan Champion. For more information, visit www.flyvax.com.

Contact:
TNG Pharmaceuticals, Inc.
Dr. Serge Martinod, CEO, 860-625-0424
serge@flyvax.com
or
Phoebe A. Wood, Executive Chairman, 502-894-0295


News Index

Venture Capital Database

Venture Capital Deals Spreadsheet

 

 NEWS

Latest VC News
VC News Archive
News Search
Venture Capital Deals
RSS News Feed

List Your Firm

Entrepreneurs
Investors
Advisors

Venture Capital Database

VCPro Database
Download Trial
Buy Now

Venture Capital Deals

vcaDeals
Download Sample
Buy Now

VC Tools

VC Pitch
Private Placement Memorandum

Business Plan Tools

Free Business Plan Template
Business Plan Tools

 

 

Copyright © 1998-2014 Access InterComm  All rights reserved. 
Site Map | Privacy Statement | Legal Notice & Disclaimer